Transthyretin Polypeptide: What This 127-Amino-Acid Protein Does

The transthyretin polypeptide is the single protein chain that makes up transthyretin (TTR), a transport protein found in human blood and cerebrospinal fluid. Each chain contains 127 amino acids, and four of these chains join together to form the tetramer that carries thyroid hormone and vitamin A through the body. When the chain misfolds, it can clump into amyloid fibrils and drive a serious condition called transthyretin amyloidosis.

What the Transthyretin Polypeptide Is

Transthyretin is encoded by the TTR gene on chromosome 18 and is produced mainly in the liver. Smaller amounts are made in the choroid plexus of the brain and in the retinal pigment epithelium of the eye.

The name is a shortened form of "transports thyroxine and retinol." That name describes its job better than any structural label, because TTR exists to move two molecules: the thyroid hormone thyroxine (T4) and retinol, the form of vitamin A that circulates in blood.

A single TTR chain weighs roughly 13.8 kDa, while the complete four-chain tetramer weighs about 55 kDa. Transthyretin is not a drug, a supplement, or a manufactured peptide. It is a natural human protein, and its presence in the bloodstream is normal and healthy.

Transthyretin Polypeptide Structure and Folding

Its polypeptide structure is dominated by beta sheets rather than the alpha helices common in many hormones. Each 127-amino-acid chain folds into a beta-sandwich made of eight beta strands, with a short alpha helix near the middle.

Two chains pair up into a dimer, and two dimers stack to form the full tetramer. The center of the tetramer has a channel that holds two thyroxine binding sites. This architecture explains why small mutations or age-related changes can destabilize the entire assembly.

Researchers often check molecular weight when they study a protein. A polypeptide calculator converts an amino acid sequence into a predicted mass, which is how a TTR monomer is confirmed at roughly 13.8 kDa. A mass that does not match usually signals a mutation, a truncation, or a chemical modification.

What Transthyretin Does in the Body

Transthyretin sits in a polypeptide group of small carrier proteins that shuttle hormones and vitamins through the bloodstream. Its main jobs include:

• Thyroxine transport: TTR carries about 10–15% of circulating T4, alongside thyroxine-binding globulin and albumin.
• Retinol transport: TTR binds retinol-binding protein, keeping vitamin A from being lost through the kidneys.
• Backup transport: If retinol-binding protein is cleaved, TTR can still help carry retinol.
• Cerebrospinal fluid: TTR made in the choroid plexus is the main thyroxine carrier in the brain and spinal fluid.

Transthyretin is not an enzyme and does not catalyze chemical reactions. It is a carrier, and its role depends entirely on staying folded into the correct tetramer shape.

When the Transthyretin Polypeptide Misfolds

Transthyretin amyloidosis (ATTR) happens when the tetramer falls apart, the monomers misfold, and the misfolded chains stack into amyloid fibrils. Those fibrils deposit in tissues, most often the heart and peripheral nerves.

There are two main forms. Wild-type ATTR occurs without a gene mutation and is most common in older men, where it causes a stiff heart muscle and heart failure. Hereditary ATTR comes from a TTR gene variant such as V30M, V122I, or T60A and can appear as early as the 30s or 40s.

Common warning signs include numbness or tingling in the hands and feet, carpal tunnel syndrome, an irregular heartbeat, shortness of breath, and unexplained weight loss. Symptoms overlap with many other conditions, so diagnosis often requires a combination of imaging, genetic testing, and sometimes a tissue biopsy.

Anyone with these symptoms should talk to a healthcare professional. Transthyretin amyloidosis is treatable, and early diagnosis generally leads to better outcomes.

Treatment Options for Transthyretin Amyloidosis

Approved therapies work in two broad ways: stabilizing the tetramer so it stays folded, or lowering the amount of TTR the body produces. The table below summarizes the main options used in the United States.

Treatment	Type	Primary Use	Notes
Tafamidis	Oral stabilizer	ATTR-CM and hereditary polyneuropathy	Binds the thyroxine binding site
Acoramidis	Oral stabilizer	ATTR-CM	Designed for near-complete stabilization
Patisiran	siRNA infusion	Hereditary ATTR polyneuropathy	Reduces TTR production in the liver
Vutrisiran	siRNA injection	Hereditary ATTR polyneuropathy	Given every three months
Inotersen or eplontersen	Antisense	Hereditary ATTR polyneuropathy	Weekly or monthly dosing
Liver transplant	Surgery	Selected hereditary cases	Replaces the main source of mutant TTR

Treatment choice depends on the type of ATTR, which organs are involved, and the patient's overall health. A cardiologist, neurologist, or genetic counselor usually guides the decision.

How Transthyretin Compares With Other Polypeptides

Other polypeptide examples such as insulin, glucagon, and GLP-1 receptor agonists are hormones or drugs built from single chains. They are given to patients, while transthyretin is made inside the body and is never prescribed as a medicine.

Commercial manufacturers such as PolyPeptide synthesize short peptide chains for pharmaceutical use, but transthyretin is not a product they make. Some polypeptide antibiotics, including vancomycin and polymyxin B, also act on bacteria rather than on thyroid hormone transport.

The key takeaway is that transthyretin is a normal human carrier protein, not a therapeutic peptide. Its clinical importance comes from what happens when its polypeptide chain loses shape and begins to deposit as amyloid.

COMMON QUESTIONS

Frequently Asked Questions

Is transthyretin a polypeptide?

Yes, transthyretin is a polypeptide because each of its four subunits is a single chain of 127 amino acids. Those four chains assemble into the functional tetramer that circulates in blood and cerebrospinal fluid.

What does the transthyretin protein do?

Transthyretin transports thyroxine, a thyroid hormone, and carries retinol-binding protein so vitamin A is not lost through the kidneys. It is made mainly in the liver, with additional production in the choroid plexus of the brain.

What causes transthyretin amyloidosis?

Transthyretin amyloidosis occurs when the tetramer dissociates and the individual chains misfold into amyloid fibrils that deposit in the heart and nerves. It can be caused by an inherited TTR gene mutation or by age-related instability in people with no mutation. Anyone with symptoms such as numbness, carpal tunnel syndrome, or unexplained heart failure should speak with a healthcare professional.